ViiV closes in on long-acting two drug HIV regimen

15 August 2018

ViiV Healthcare, the HIV-focused drugmaker that is majority-owned by UK pharma major GlaxoSmithKline (LSE: GSK), has taken another step forward with a two-drug regimen for the virus.

New data suggests that it could soon have the first once-monthly two-drug combination on the market, following on from a milestone achieved by ViiV in November 2017.

That month, the company received US approval for Juluca (dolutegravir/rilpivirine), the first complete treatment regimen containing only two drugs to treat certain adults with HIV-1, aimed at lessening the toxicity and side effect burden of current treatments that combine three or four medicines.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK